Pfizer Price to Sales Ratio 2010-2024 | PFE
Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of July 26, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Pfizer P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-07-26 |
30.77 |
|
3.19 |
| 2024-03-31 |
26.97 |
$9.64 |
2.80 |
| 2023-12-31 |
27.56 |
$10.26 |
2.69 |
| 2023-09-30 |
31.32 |
$12.04 |
2.60 |
| 2023-06-30 |
34.25 |
$13.65 |
2.51 |
| 2023-03-31 |
37.69 |
$16.28 |
2.31 |
| 2022-12-31 |
46.90 |
$17.51 |
2.68 |
| 2022-09-30 |
39.71 |
$17.45 |
2.28 |
| 2022-06-30 |
47.20 |
$17.69 |
2.67 |
| 2022-03-31 |
46.24 |
$16.16 |
2.86 |
| 2021-12-31 |
52.35 |
$14.27 |
3.67 |
| 2021-09-30 |
37.80 |
$12.12 |
3.12 |
| 2021-06-30 |
34.10 |
$9.75 |
3.50 |
| 2021-03-31 |
31.24 |
$8.17 |
3.82 |
| 2020-12-31 |
31.40 |
$7.41 |
4.24 |
| 2020-09-30 |
29.38 |
$5.70 |
5.15 |
| 2020-06-30 |
25.92 |
$6.12 |
4.23 |
| 2020-03-31 |
25.61 |
$6.70 |
3.82 |
| 2019-12-31 |
30.43 |
$7.19 |
4.23 |
| 2019-09-30 |
27.64 |
$7.06 |
3.92 |
| 2019-06-30 |
33.01 |
$7.03 |
4.69 |
| 2019-03-31 |
32.08 |
$6.96 |
4.61 |
| 2018-12-31 |
32.69 |
$6.81 |
4.80 |
| 2018-09-30 |
32.75 |
$8.88 |
3.69 |
| 2018-06-30 |
26.73 |
$8.83 |
3.03 |
| 2018-03-31 |
25.90 |
$8.71 |
2.97 |
| 2017-12-31 |
26.19 |
$8.68 |
3.02 |
| 2017-09-30 |
25.58 |
$8.63 |
2.97 |
| 2017-06-30 |
23.84 |
$8.57 |
2.78 |
| 2017-03-31 |
24.05 |
$8.57 |
2.81 |
| 2016-12-31 |
22.60 |
$8.56 |
2.64 |
| 2016-09-30 |
23.34 |
$8.59 |
2.72 |
| 2016-06-30 |
24.05 |
$8.41 |
2.86 |
| 2016-03-31 |
20.07 |
$8.17 |
2.46 |
| 2015-12-31 |
21.64 |
$7.81 |
2.77 |
| 2015-09-30 |
20.88 |
$7.60 |
2.75 |
| 2015-06-30 |
22.12 |
$7.60 |
2.91 |
| 2015-03-31 |
22.76 |
$7.68 |
2.96 |
| 2014-12-31 |
20.20 |
$7.71 |
2.62 |
| 2014-09-30 |
19.01 |
$7.63 |
2.49 |
| 2014-06-30 |
18.92 |
$7.60 |
2.49 |
| 2014-03-31 |
20.29 |
$7.44 |
2.73 |
| 2013-12-31 |
19.18 |
$7.40 |
2.59 |
| 2013-09-30 |
17.85 |
$7.14 |
2.50 |
| 2013-06-30 |
17.27 |
$6.97 |
2.48 |
| 2013-03-31 |
17.64 |
$7.00 |
2.52 |
| 2012-12-31 |
15.20 |
$7.25 |
2.10 |
| 2012-09-30 |
14.92 |
$6.99 |
2.13 |
| 2012-06-30 |
13.69 |
$7.39 |
1.85 |
| 2012-03-31 |
13.35 |
$7.62 |
1.75 |
| 2011-12-31 |
12.62 |
$7.71 |
1.64 |
| 2011-09-30 |
10.21 |
$8.17 |
1.25 |
| 2011-06-30 |
11.77 |
$8.03 |
1.47 |
| 2011-03-31 |
11.49 |
$8.08 |
1.42 |
| 2010-12-31 |
9.80 |
$8.07 |
1.21 |
| 2010-09-30 |
9.51 |
$8.40 |
1.13 |
| 2010-06-30 |
7.82 |
$8.13 |
0.96 |
| 2010-03-31 |
9.30 |
$7.63 |
1.22 |
| 2009-12-31 |
9.77 |
$7.20 |
1.36 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$171.018B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
